Top Small Cap Stocks To Add to Your Watchlist – May 6th

by · The Cerbat Gem

Inflection Point Acquisition Corp. II, POET Technologies, Wolfspeed, Avalo Therapeutics, Direxion Daily PLTR Bear 1X Shares, Ernexa Therapeutics, and Inflection Point Acquisition are the seven Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small-cap stocks are shares of companies with relatively small market capitalizations—commonly defined as firms with total market values roughly between $300 million and $2 billion, though exact cutoffs vary by index and over time. Investors view them as offering higher growth potential but also greater volatility, lower liquidity, and higher risk compared with mid- and large-cap stocks. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

Inflection Point Acquisition Corp. II (IPXX)

Read Our Latest Research Report on IPXX

POET Technologies (POET)

POET Technologies Inc. designs, develops, manufactures, and sells discrete and integrated opto-electronic solutions in Canada, the United States, Singapore, and China. It offers integration solutions based on the POET Optical Interposer, a novel platform that allows the seamless integration of electronic and photonic devices into a single multi-chip module using advanced wafer-level semiconductor manufacturing techniques.

Read Our Latest Research Report on POET

Wolfspeed (WOLF)

Wolfspeed, Inc. operates as a powerhouse semiconductor company focuses on silicon carbide and gallium nitride (GaN) technologies in Europe, Hong Kong, China, rest of Asia-Pacific, the United States, and internationally. It offers silicon carbide and GaN materials, including silicon carbide bare wafers, epitaxial wafers, and GaN epitaxial layers on silicon carbide wafers to manufacture products for RF, power, and other applications.

Read Our Latest Research Report on WOLF

Avalo Therapeutics (AVTX)

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

Read Our Latest Research Report on AVTX

Direxion Daily PLTR Bear 1X Shares (PLTD)

Read Our Latest Research Report on PLTD

Ernexa Therapeutics (ERNA)

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.

Read Our Latest Research Report on ERNA

Inflection Point Acquisition (IPAX)

Read Our Latest Research Report on IPAX

Recommended Stories